Ovarian Cancer

Lung Cancer

The use of immunotherapy agents for the treatment of gynecologic cancers is currently a hot topic in the field, with various clinical trials ongoing. The success of PARP inhibitors has also exploded over the past year, translating to improvements in progression-free survival and quality of life for some patients, says Erin K. Crane, MPH, MD.

David O'Malley, MD, discusses the excitement surrounding PARP inhibitors for patients with ovarian cancer.

Lung Cancer

Kathleen Moore, MD, associate director for clinical research at the Stephenson Oklahoma Cancer Center, discusses the development of combination therapy strategies for patients with ovarian cancer.

Rebecca C. Arend, MD, discusses novel combinations being investigated for the treatment of patients with ovarian cancer.

Kathleen Moore, MD,&nbsp;discusses combination strategies with immunotherapy for patients with ovarian cancer during the&nbsp;2018 Society of Gynecologic Oncology Annual Winter Meeting.<br /> &nbsp;

During the 2018 Society of Gynecologic Oncology Annual Winter Meeting, Camille Gunderson, MD,&nbsp;detailed some of the active trials currently exploring PARP inhibitors in combination with either anti-VEGF therapy or immunotherapy in ovarian cancer.

Women with newly diagnosed stage III&nbsp;epithelial ovarian cancer experienced an improvement in&nbsp;relapse-free survival and overall survival with the addition of&nbsp;hyperthermic intraperitoneal chemotherapy to interval cytoreductive surgery, according to results&nbsp;from a multicenter, open-label, phase III trial.

According to results of an open-label, single-center, 2-stage, proof-of-concept phase II study, prexasertib (LY2606368), a cell cycle checkpoint kinase 1 and 2 inhibitor, demonstrated clinical activity and was tolerable in&nbsp;women with measurable, recurrent high-grade serous or high-grade endometrioid ovarian carcinoma.

Cristiana Sessa, MD, head of Phase I-II Unit and Pharmacology, vice head of Medical Oncology and Head of Clinical Research, Oncology Institute of Southern Switzerland, discusses targeted therapies for <em>BRCA</em>1/2-mutated tumors.&nbsp;

Hackensack Meridian Health has announced that Verda J. Hicks, MD, FACS, FACOG, will serve as its chief of Gynecologic Oncology at Jersey Shore University Medical Center. She will be joined by associates James R. Bosscher, MD, and Karim ElSahwi, MD, to facilitate promising experience and care to the Monmouth, Ocean, and Middlesex counties.